Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Down 42.2% in December

Artelo Biosciences, Inc. (NASDAQ:ARTL) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totalling 18,600 shares, a drop of 42.2% from the December 15th total of 32,200 shares. Based on an average daily trading volume, of 31,600 shares, the short-interest ratio is currently 0.6 days. Currently, 0.6% of the shares of the stock are sold short.

Analysts Set New Price Targets

Several brokerages recently issued reports on ARTL. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Artelo Biosciences in a research note on Monday, December 9th. D. Boral Capital restated a “buy” rating and issued a $6.00 price target on shares of Artelo Biosciences in a research report on Tuesday. EF Hutton Acquisition Co. I upgraded Artelo Biosciences to a “strong-buy” rating in a research report on Tuesday, October 1st. Finally, LADENBURG THALM/SH SH raised Artelo Biosciences to a “strong-buy” rating in a research note on Wednesday, December 25th.

Artelo Biosciences Trading Up 1.3 %

Artelo Biosciences stock traded up $0.02 during mid-day trading on Wednesday, hitting $1.16. The company’s stock had a trading volume of 13,430 shares, compared to its average volume of 32,784. The stock’s fifty day moving average is $1.09 and its two-hundred day moving average is $1.19. The firm has a market capitalization of $3.73 million, a PE ratio of -0.40 and a beta of 1.25. Artelo Biosciences has a 1 year low of $0.91 and a 1 year high of $1.75.

Artelo Biosciences (NASDAQ:ARTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. On average, equities analysts expect that Artelo Biosciences will post -2.62 EPS for the current fiscal year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.